内镜鼻窦手术后难治性原发性慢性鼻窦炎的预测因素
本研究基于TriNetX网络纳入24759例2015年后行FESS的原发性CRS成人患者,采用包含修正手术和/或生物制剂启动的复合结局定义难治性CRS。11.6%患者出现难治性CRS,哮喘是最强预测因素(HR 2.06),其次为镇痛药过敏、鼻息肉等2型炎症共病。将生物制剂纳入结局定义可为风险分层和术后咨询提供当代框架。
要点
- 哮喘是FESS后难治性CRS最强预测因素(HR 2.06)。
- 镇痛药过敏、鼻息肉、COPD、嗜酸性粒细胞增多亦为独立预测因素。
- 复合结局定义(修正手术和/或生物制剂)优于仅用修正手术。
核心结论
- FESS后难治性CRS与2型炎症共病及特定人口学因素强烈相关。
- 将生物制剂纳入结局定义可为风险分层和术后咨询提供当代框架。
研究设计与样本
- 基于TriNetX研究网络的回顾性队列研究,纳入2015年后行FESS的成人原发性CRS患者。
- 排除继发性CRS、既往生物制剂治疗或鼻窦肿瘤患者,最终纳入24759例。
- 主要结局为难治性CRS,定义为术后3个月至5年内行修正FESS或启动生物制剂。
- 采用Cox比例风险模型结合逐步选择法评估术前协变量。
主要发现
- 24759例患者中2866例(11.6%)出现难治性CRS。
- 难治性患者中66.6%行修正FESS,42.0%启动生物制剂,8.7%同时行修正手术和启动生物制剂。
- 多变量分析中哮喘是最强预测因素(HR 2.06,p < 0.001)。
- 其他预测因素包括镇痛药过敏(如NSAIDs)(HR 1.87,p < 0.001)、鼻息肉(HR 1.67,p < 0.001)、食物过敏(HR 1.37,p = 0.096)、COPD(HR 1.27,p = 0.006)、嗜酸性粒细胞增多(HR 1.27,p < 0.001)、黑人或非裔美国人种族(HR 1.16,p = 0.044)。
临床怎么用
- 对于合并哮喘、镇痛药过敏、鼻息肉等2型炎症共病的CRS患者,术后应加强监测和风险咨询。
- 难治性CRS的评估应同时考虑修正手术和生物制剂启动,而非仅关注修正手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Refractory chronic rhinosinusitis (CRS) after functional endoscopic sinus surgery (FESS) has traditionally been defined by revision surgery alone. With the emergence of biologic therapies, treatment escalation now includes revision surgery and/or biologic initiation. We sought to identify independent predictors of refractory primary CRS using a composite outcome incorporating surgery and/or biologic initiation. METHODS: Adult patients with primary CRS undergoing FESS after 2015 were identified in the TriNetX Research Network. Patients with secondary CRS, prior biologic therapy, or sinonasal neoplasms were excluded. The primary outcome was refractory CRS, defined as revision FESS or biologic initiation from 3 months to 5 years postoperatively. Preoperative covariates were evaluated using Cox proportional hazards modeling with stepwise selection. RESULTS: Among 24,759 patients, 2866 (11.6%) had refractory CRS after FESS. Of these, 66.6% underwent revision FESS, 42.0% initiated biologic therapy, and 8.7% had revision surgery and initiated a biologic therapy. In multivariable analysis, asthma was the strongest predictor (HR 2.06, p < 0.001), followed by allergy to analgesic agents (e.g., NSAIDs) (HR 1.87, p < 0.001), nasal polyps (HR 1.67, p < 0.001), food allergy (HR 1.37, p = 0.096), COPD (HR 1.27, p = 0.006), eosinophilia (HR 1.27, p < 0.001), and Black or African American race (HR 1.16, p = 0.044). CONCLUSION: Refractory CRS following FESS is strongly associated with type 2 inflammatory comorbidities and select demographic factors. Incorporating biologic therapy into outcome definitions provides a contemporary framework for risk stratification and postoperative counseling.
引用
- Khaderi IM, Tochigi K, Barefoot NR, et al. Predictors of Refractory Primary Chronic Rhinosinusitis Following Endoscopic Sinus Surgery. Int Forum Allergy Rhinol. 2026. PMID: 42716515. doi:10.1002/alr.70267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。